Compare Atmos Energy Corporation (ATO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Viatris Inc — how do they compare? Atmos Energy Corporation trades at $168.76 (market cap $28.59B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Atmos Energy Corporation is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| ATO | VTRS | |
|---|---|---|
Market Cap | $28.59B | $18.69B |
Sector | Utilities | Health |
52-Week High | $192.25 | $17.86 |
52-Week Low | $162.44 | $9.49 |
Enterprise Value | $38.40B | $30.80B |
Dividend Yield | 2.36% | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
